董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Louis Lange | 男 | Non-Executive Director | 77 | 67.39万美元 | 未持股 | 2026-02-18 |
| Adele Gulfo | 女 | Non-Executive Director | 63 | 62.00万美元 | 未持股 | 2026-02-18 |
| Michael Davidson | 男 | Chief Executive Officer and Executive Director | 69 | 1364.19万美元 | 未持股 | 2026-02-18 |
| Wouter Joustra | 男 | Non-Executive Director | 37 | 4.30万美元 | 未持股 | 2026-02-18 |
| Mark C. McKenna | 男 | Non-Executive Director and Vice Chair | 46 | 66.39万美元 | 未持股 | 2026-02-18 |
| John Kastelein | 男 | Chief Scientific Officer and Non-Executive Director | 72 | 481.21万美元 | 未持股 | 2026-02-18 |
| Janneke van der Kamp | 女 | Non-Executive Director | 50 | 65.14万美元 | 未持股 | 2026-02-18 |
| Wouter Joustra | 男 | Non-Executive Director | 37 | 未披露 | 未持股 | 2026-02-18 |
| James N. Topper | 男 | Non-Executive Director | 64 | 4.30万美元 | 未持股 | 2026-02-18 |
| William H. Lewis | 男 | Chair and Non-Executive Director | 57 | 69.39万美元 | 未持股 | 2026-02-18 |
| John W. Smither | 男 | Non-Executive Director | 73 | 67.64万美元 | 未持股 | 2026-02-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Davidson | 男 | Chief Executive Officer and Executive Director | 69 | 1364.19万美元 | 未持股 | 2026-02-18 |
| John Kastelein | 男 | Chief Scientific Officer and Non-Executive Director | 72 | 481.21万美元 | 未持股 | 2026-02-18 |
| Louise Kooij | 女 | Chief Accounting Officer | 50 | 223.57万美元 | 未持股 | 2026-02-18 |
| Ian Somaiya | 男 | Chief Financial Officer | 52 | 469.79万美元 | 未持股 | 2026-02-18 |
董事简历
中英对照 | 中文 | 英文- Louis Lange
-
Louis Lange，医学博士，自2022年9月起担任Epiphany Technology Acquisition Corp.的董事之一，作为生物技术领域领先的企业家、投资者和学术带头人，拥有漫长而卓越的职业生涯。Lange博士于1992年创立了CV Therapeutics，Inc.“CVT”和Nasdaq：CVTX，一家专注于心血管疾病的生物技术公司，并担任其董事长、首席执行官和首席科学官。Lange博士在获得5000万美元风险投资后，于1996年首次公开发行CVT，并监督了CVT的商业成功，引领了Ranexa和Lexiscan的增长，这两种药物的年销售额合计超过15亿美元。2009年，Lange博士将CVT以14亿美元的价格卖给了吉利德科学公司（Nasdaq：GILD），并在2019年之前一直担任兼职，担任高级顾问，在2018年之前向吉利德科学公司的首席执行官汇报工作。在成功销售CVT之后，Lange博士创立并出售了另外两家生物技术公司。2017年，GE Healthcare收购了其中一家公司Rapidscan Pharma Solutions Inc.（“RPS”），后者是一家用于心血管疾病诊断的生物制药应激剂开发商。2015年，Audentes Therapeutics, Inc.（Nasdaq：BOLD）收购了其中的第二家公司——基因治疗产品开发商Cardiogen Sciences，Inc；Lange博士继续担任首席董事，直到2020年以31亿美元将Audentes Therapeutics出售给Astellas Pharma Inc.（TYO：4503）。目前，Lange博士是Asset Management Ventures（以下简称“AMV”）的合伙人，该公司是一家早期风险投资公司，专注于数字健康、技术和生命科学领域的投资，处于生物技术领域关键创新趋势和交易流程的前沿。兰格博士在生物技术公司的各个领域领导了超过12项投资。除了Lange博士的运营和投资经验外，Lange博士在哈佛大学和华盛顿大学的学术医学领域工作了22年，他曾于1985-1992年在华盛顿大学医学院的犹太医院担任心脏病学主任和医学教授，并且是分子心脏病学领域的首批院士之一。目前，Lange博士担任罗切斯特大学董事会成员，自1998年以来一直担任这一职务。作为负责监督所有医疗业务的卫生事务委员会主席，Lange博士一直是医疗中心战略振兴领导团队的一员，负责监督项目，包括建造两座研究大楼和招聘100多名教职员工。Lange还领导了生物技术领域最受尊敬的行业和行业协会。从1999年到2009年，Lange博士担任生物技术创新组织的董事会成员，该组织是生物技术公司的贸易组织，领导了最大的成员公司委员会两年。Lange博士曾在非营利和营利性领域的许多其他公共和私人委员会任职，包括系统生物学研究所（“ISB”）和加州大学旧金山分校格拉德斯通研究所（UCSF Gladstone Institute），这是一个独立的、非营利性的生命科学研究机构，位于旧金山湾区生物医学和技术创新的中心。Lange拥有罗切斯特大学的学士学位、哈佛大学的医学博士学位和哈佛大学的生物化学博士学位。
Louis Lange has served as a member of the Board of Directors since November 2022. Dr. Lange previoly served on the NewAmsterdam Pharma board from 2021 to November 2022. Dr. Lange previoly served as the chief of cardiology and a professor of medicine at the Washington University School of Medicine and was one of the early academicians in molecular cardiology. Dr. Lange founded and served as the chief executive officer and chairman of CV Therapeutics, Inc. (Nasdaq: CVTX) from 1990 until 2019, and as a senior advisor to Gilead Sciences, Inc. from 2009 until 2019, following its acquisition of CV Therapeutics. Dr. Lange currently serves as a general partner with Asset Management Ventures. Dr. Lange also serves on the board of directors of private companies Stealth Biotherapeutics Corp., Amygdala Neurosciences, Inc. and Incendia Therapeutics, Inc. Dr. Lange previoly served on the board of directors of Audentes Therapeutics, Inc. (sold to Astellas Pharma Inc.) and CymaBay Therapeutics (acquired by Gilead). Dr. Lange has a Bachelor's degree from the University of Rochester, an M.D. from Harvard University and a Ph.D. in Biological Chemistry, also from Harvard University. - Louis Lange，医学博士，自2022年9月起担任Epiphany Technology Acquisition Corp.的董事之一，作为生物技术领域领先的企业家、投资者和学术带头人，拥有漫长而卓越的职业生涯。Lange博士于1992年创立了CV Therapeutics，Inc.“CVT”和Nasdaq：CVTX，一家专注于心血管疾病的生物技术公司，并担任其董事长、首席执行官和首席科学官。Lange博士在获得5000万美元风险投资后，于1996年首次公开发行CVT，并监督了CVT的商业成功，引领了Ranexa和Lexiscan的增长，这两种药物的年销售额合计超过15亿美元。2009年，Lange博士将CVT以14亿美元的价格卖给了吉利德科学公司（Nasdaq：GILD），并在2019年之前一直担任兼职，担任高级顾问，在2018年之前向吉利德科学公司的首席执行官汇报工作。在成功销售CVT之后，Lange博士创立并出售了另外两家生物技术公司。2017年，GE Healthcare收购了其中一家公司Rapidscan Pharma Solutions Inc.（“RPS”），后者是一家用于心血管疾病诊断的生物制药应激剂开发商。2015年，Audentes Therapeutics, Inc.（Nasdaq：BOLD）收购了其中的第二家公司——基因治疗产品开发商Cardiogen Sciences，Inc；Lange博士继续担任首席董事，直到2020年以31亿美元将Audentes Therapeutics出售给Astellas Pharma Inc.（TYO：4503）。目前，Lange博士是Asset Management Ventures（以下简称“AMV”）的合伙人，该公司是一家早期风险投资公司，专注于数字健康、技术和生命科学领域的投资，处于生物技术领域关键创新趋势和交易流程的前沿。兰格博士在生物技术公司的各个领域领导了超过12项投资。除了Lange博士的运营和投资经验外，Lange博士在哈佛大学和华盛顿大学的学术医学领域工作了22年，他曾于1985-1992年在华盛顿大学医学院的犹太医院担任心脏病学主任和医学教授，并且是分子心脏病学领域的首批院士之一。目前，Lange博士担任罗切斯特大学董事会成员，自1998年以来一直担任这一职务。作为负责监督所有医疗业务的卫生事务委员会主席，Lange博士一直是医疗中心战略振兴领导团队的一员，负责监督项目，包括建造两座研究大楼和招聘100多名教职员工。Lange还领导了生物技术领域最受尊敬的行业和行业协会。从1999年到2009年，Lange博士担任生物技术创新组织的董事会成员，该组织是生物技术公司的贸易组织，领导了最大的成员公司委员会两年。Lange博士曾在非营利和营利性领域的许多其他公共和私人委员会任职，包括系统生物学研究所（“ISB”）和加州大学旧金山分校格拉德斯通研究所（UCSF Gladstone Institute），这是一个独立的、非营利性的生命科学研究机构，位于旧金山湾区生物医学和技术创新的中心。Lange拥有罗切斯特大学的学士学位、哈佛大学的医学博士学位和哈佛大学的生物化学博士学位。
- Louis Lange has served as a member of the Board of Directors since November 2022. Dr. Lange previoly served on the NewAmsterdam Pharma board from 2021 to November 2022. Dr. Lange previoly served as the chief of cardiology and a professor of medicine at the Washington University School of Medicine and was one of the early academicians in molecular cardiology. Dr. Lange founded and served as the chief executive officer and chairman of CV Therapeutics, Inc. (Nasdaq: CVTX) from 1990 until 2019, and as a senior advisor to Gilead Sciences, Inc. from 2009 until 2019, following its acquisition of CV Therapeutics. Dr. Lange currently serves as a general partner with Asset Management Ventures. Dr. Lange also serves on the board of directors of private companies Stealth Biotherapeutics Corp., Amygdala Neurosciences, Inc. and Incendia Therapeutics, Inc. Dr. Lange previoly served on the board of directors of Audentes Therapeutics, Inc. (sold to Astellas Pharma Inc.) and CymaBay Therapeutics (acquired by Gilead). Dr. Lange has a Bachelor's degree from the University of Rochester, an M.D. from Harvard University and a Ph.D. in Biological Chemistry, also from Harvard University.
- Adele Gulfo
-
Adele Gulfo自2020年5月起担任我们的临时首席商务官，并在生物制药公司Sumitovant Biopharma，Inc.（Sumitovant的子公司）担任首席业务和商业开发官，自2019年12月起，她负责监督跨多种渠道的全球业务开发和商业化活动。住友制药（Sumitovant）是住友大日本制药（Sumitomo Dainippon Pharma）的全资子公司，于2019年12月经营着从我们的前控股股东Roivant收购的五家生物制药公司，是我们的大股东。从2018年5月至2019年12月，Gulfo女士担任制药公司Roivant的商业开发主管，负责指导业务开发活动并监督商业化战略。在2018年5月加入Roivant之前，古尔弗曾担任全球制药公司MylanN.V.（McKinsey）的执行Vice President和全球商业开发主管，从2014年1月至2018年1月，她负责开发和实施生物仿制药，品牌仿制药和特种药品的营销和商业化战略。在加入Mylan之前，Gulfo女士在辉瑞公司工作了五年，担任过多个执行职位，包括美国初级保健部门的总裁兼总经理。加入Pfizer公司之前，她曾担任AstraZeneca Pharmaceuticals公司、Warner-Lambert公司（后来与Pfizer公司合并）的Parke-Davis部门的多种执行职务，也曾担任高级董事，为该公司的心血管营销，她推出了Lipitor，最畅销的制药产品。Gulfo女士目前担任EnproIndustries，Inc.（一家生产专有工程工业产品的公司）和Medexus Pharmaceuticals，Inc.（一家制药公司）的董事会成员。2015年6月至2019年6月，Gulfo女士担任制造公司BemisCompany，Inc.的董事会成员。Gulfo女士还在Partners梦百合的创新成长委员会任职，并且是Springboard生命科学公司的顾问。Gulfo女士在Seton Hall University获得生物学学士学位，在Fairleigh Dickinson University-Florham Campus获得市场营销工商管理硕士学位（最高荣誉）。她曾学习研究生分子生物学，并在新泽西大学（the University of Medicine and Dentrestry of New Jersey）开始她的职业生涯。
Adele Gulfo,Since December 2019 Ms. Gulfo has served as Chief Commercial and Business Development Officer at Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd., in which capacity she is responsible for overseeing global business development and commercialization activities across a diverse pipeline. Sumitovant Biopharma Ltd. is our majority shareholder and a wholly-owned subsidiary of Sumitomo Dainippon Pharma. From May 2020 to March 2021 Ms. Gulfo served as the Interim Chief Commercial Officer of Myovant Sciences, Inc. From May 2018 to December 2019 Ms. Gulfo served as Chief of Commercial Development at Roivant, a pharmaceutical company, in which capacity she was responsible for directing business development activities and overseeing commercialization strategies. Prior to joining Roivant in May 2018 Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V., a global pharmaceuticals company, from January 2014 to January 2018 in which capacity she was responsible for developing and implementing strategies of marketing and commercialization of biosimilars, branded generic, and specialty pharmaceutical products. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care. She also ran Commercial Operations and the Managed Markets organization across Pfizer’s biopharmaceutical business in the U.S. Prior to joining Pfizer, she held several executive positions at AstraZeneca Pharmaceuticals and at the Parke-Davis division of Warner-Lambert which later merged with Pfizer, and, as the Senior Director, Cardiovascular Marketing for that company, she launched Lipitor, the best-selling pharmaceutical product. Ms. Gulfo currently serves on the board of directors of EnPro Industries, Inc., a company producing proprietary engineered industrial products, and Medexus Pharmaceuticals, Inc., a pharmaceutical company. From June 2015 to June 2019 Ms. Gulfo served on the board of directors of Bemis Company, Inc., a manufacturing company. Ms. Gulfo also serves on the Innovation Growth Board for Partners Healthcare and is an advisor for Springboard Life Sciences. Ms. Gulfo received her B.S. in Biology from Seton Hall University, and her M.B.A. (with highest honors) in Marketing from Fairleigh Dickinson University-Florham Campus. She studied post-graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey. - Adele Gulfo自2020年5月起担任我们的临时首席商务官，并在生物制药公司Sumitovant Biopharma，Inc.（Sumitovant的子公司）担任首席业务和商业开发官，自2019年12月起，她负责监督跨多种渠道的全球业务开发和商业化活动。住友制药（Sumitovant）是住友大日本制药（Sumitomo Dainippon Pharma）的全资子公司，于2019年12月经营着从我们的前控股股东Roivant收购的五家生物制药公司，是我们的大股东。从2018年5月至2019年12月，Gulfo女士担任制药公司Roivant的商业开发主管，负责指导业务开发活动并监督商业化战略。在2018年5月加入Roivant之前，古尔弗曾担任全球制药公司MylanN.V.（McKinsey）的执行Vice President和全球商业开发主管，从2014年1月至2018年1月，她负责开发和实施生物仿制药，品牌仿制药和特种药品的营销和商业化战略。在加入Mylan之前，Gulfo女士在辉瑞公司工作了五年，担任过多个执行职位，包括美国初级保健部门的总裁兼总经理。加入Pfizer公司之前，她曾担任AstraZeneca Pharmaceuticals公司、Warner-Lambert公司（后来与Pfizer公司合并）的Parke-Davis部门的多种执行职务，也曾担任高级董事，为该公司的心血管营销，她推出了Lipitor，最畅销的制药产品。Gulfo女士目前担任EnproIndustries，Inc.（一家生产专有工程工业产品的公司）和Medexus Pharmaceuticals，Inc.（一家制药公司）的董事会成员。2015年6月至2019年6月，Gulfo女士担任制造公司BemisCompany，Inc.的董事会成员。Gulfo女士还在Partners梦百合的创新成长委员会任职，并且是Springboard生命科学公司的顾问。Gulfo女士在Seton Hall University获得生物学学士学位，在Fairleigh Dickinson University-Florham Campus获得市场营销工商管理硕士学位（最高荣誉）。她曾学习研究生分子生物学，并在新泽西大学（the University of Medicine and Dentrestry of New Jersey）开始她的职业生涯。
- Adele Gulfo,Since December 2019 Ms. Gulfo has served as Chief Commercial and Business Development Officer at Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd., in which capacity she is responsible for overseeing global business development and commercialization activities across a diverse pipeline. Sumitovant Biopharma Ltd. is our majority shareholder and a wholly-owned subsidiary of Sumitomo Dainippon Pharma. From May 2020 to March 2021 Ms. Gulfo served as the Interim Chief Commercial Officer of Myovant Sciences, Inc. From May 2018 to December 2019 Ms. Gulfo served as Chief of Commercial Development at Roivant, a pharmaceutical company, in which capacity she was responsible for directing business development activities and overseeing commercialization strategies. Prior to joining Roivant in May 2018 Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V., a global pharmaceuticals company, from January 2014 to January 2018 in which capacity she was responsible for developing and implementing strategies of marketing and commercialization of biosimilars, branded generic, and specialty pharmaceutical products. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care. She also ran Commercial Operations and the Managed Markets organization across Pfizer’s biopharmaceutical business in the U.S. Prior to joining Pfizer, she held several executive positions at AstraZeneca Pharmaceuticals and at the Parke-Davis division of Warner-Lambert which later merged with Pfizer, and, as the Senior Director, Cardiovascular Marketing for that company, she launched Lipitor, the best-selling pharmaceutical product. Ms. Gulfo currently serves on the board of directors of EnPro Industries, Inc., a company producing proprietary engineered industrial products, and Medexus Pharmaceuticals, Inc., a pharmaceutical company. From June 2015 to June 2019 Ms. Gulfo served on the board of directors of Bemis Company, Inc., a manufacturing company. Ms. Gulfo also serves on the Innovation Growth Board for Partners Healthcare and is an advisor for Springboard Life Sciences. Ms. Gulfo received her B.S. in Biology from Seton Hall University, and her M.B.A. (with highest honors) in Marketing from Fairleigh Dickinson University-Florham Campus. She studied post-graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey.
- Michael Davidson
-
Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
Michael Davidson has served as Chief Executive Officer and executive director since November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from Augt 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid loring drugs, and omega 3 fatty acids. Dr. Davidson is board certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX), and BioAge Labs, Inc. (Nasdaq: BIOA). Dr. Davidson also serves on the boards of f private biotechnology companies, Sonothera, Jocasta Neuroscience and Abcentra. Dr. Davidson received his B.A. and M.S. from Northstern University and his M.D. from The Ohio State University School of Medicine. - Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
- Michael Davidson has served as Chief Executive Officer and executive director since November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from Augt 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid loring drugs, and omega 3 fatty acids. Dr. Davidson is board certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX), and BioAge Labs, Inc. (Nasdaq: BIOA). Dr. Davidson also serves on the boards of f private biotechnology companies, Sonothera, Jocasta Neuroscience and Abcentra. Dr. Davidson received his B.A. and M.S. from Northstern University and his M.D. from The Ohio State University School of Medicine.
- Wouter Joustra
-
董事会非独立成员Wouter Joustra于2019年加入Forbion，担任合伙人，目前担任Forbion Growth Fund的普通合伙人。在Forbion，Wouter负责交易发起、投资组合管理和撤资策略。此前，Wouter是Kempen&Co的高级交易员生命科学和医疗保健，这是一家欧洲投资银行，拥有专门的生命科学和医疗保健专营权。在这个职位上，他负责积极运营Kempen&Co的交易组合，在那里他参与交易结构，股权资本市场交易，以及公司股票的大宗交易。在Kempen&Co，Wouter也是生命科学专营权的执行董事会成员，负责定义和执行利基的战略和预算。Wouter拥有硕士学位。荷兰格罗宁根大学工商管理专业。
Wouter Joustra has served as a member of the Board since May 15, 2024. He is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, Mr. Jotra is responsible for deal origination, general portfolio management and divestment strategies, and foces on Forbion's Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Prior to joining Forbion in 2019, Mr. Jotra previoly was a Senior Trader, as ll as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. In this role, Mr. Jotra managed Kempen's trading portfolio, and was involved in deal structuring and equity capital markets transactions, as ll as larger block trades. Mr. Jotra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion European Acquisition Corp. until the completion of the biness combination of enGene Holdings Inc. in October 2023. Currently Mr. Jotra serves on the board of directors of VectorY Therapeutics, Beacon Therapeutics, Navigator Medicines, Verdiva Bio and NewAmsterdam Pharma N.V. (NASDAQ: NAMS). Mr. Jotra holds an M.Sc. in Biness Administration and a B.Sc. in International Biness and Management from the University of Groningen. - 董事会非独立成员Wouter Joustra于2019年加入Forbion，担任合伙人，目前担任Forbion Growth Fund的普通合伙人。在Forbion，Wouter负责交易发起、投资组合管理和撤资策略。此前，Wouter是Kempen&Co的高级交易员生命科学和医疗保健，这是一家欧洲投资银行，拥有专门的生命科学和医疗保健专营权。在这个职位上，他负责积极运营Kempen&Co的交易组合，在那里他参与交易结构，股权资本市场交易，以及公司股票的大宗交易。在Kempen&Co，Wouter也是生命科学专营权的执行董事会成员，负责定义和执行利基的战略和预算。Wouter拥有硕士学位。荷兰格罗宁根大学工商管理专业。
- Wouter Joustra has served as a member of the Board since May 15, 2024. He is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, Mr. Jotra is responsible for deal origination, general portfolio management and divestment strategies, and foces on Forbion's Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Prior to joining Forbion in 2019, Mr. Jotra previoly was a Senior Trader, as ll as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. In this role, Mr. Jotra managed Kempen's trading portfolio, and was involved in deal structuring and equity capital markets transactions, as ll as larger block trades. Mr. Jotra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion European Acquisition Corp. until the completion of the biness combination of enGene Holdings Inc. in October 2023. Currently Mr. Jotra serves on the board of directors of VectorY Therapeutics, Beacon Therapeutics, Navigator Medicines, Verdiva Bio and NewAmsterdam Pharma N.V. (NASDAQ: NAMS). Mr. Jotra holds an M.Sc. in Biness Administration and a B.Sc. in International Biness and Management from the University of Groningen.
- Mark C. McKenna
-
Mark C. McKenna，已同意在Perceptive Capital Solutions Corp董事会任职。McKenna先生自2024年2月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE）的董事，自2024年2月起担任Helix Acquisition Corp. II（纳斯达克：HLXB）的董事，自2024年2月起担任Arch Venture Partner的风险合伙人，自2023年8月起担任Apogee Therapeutics，Inc.（纳斯达克：AGE）的董事会主席。自2023年6月以来，McKenna先生还担任McKenna Capital Partners的首席投资官和董事总经理，这是一家致力于投资于使人衰弱的疾病的突破性治疗的家族办公室。McKenna先生最近于2019年9月至2023年6月（当时Prometheus被默克制药公司（NYSE：MRK）收购）期间担任临床阶段生物技术公司Prometheus Biosciences, Inc.（“Prometheus”）的总裁兼首席执行官和董事会成员，并于2021年8月至2023年6月担任Prometheus董事会主席。在加入普罗米修斯之前，他曾于2016年3月至2019年8月担任柳药医疗，Inc.（“Salix”）总裁，该公司是一家制药公司，是Bausch Health健康公司（纽约证券交易所代码：BHC）的全资子公司。在加入Salix之前，McKenna先生曾在Bausch + Lomb担任过十多年的各种职务，该公司也是Bausch Health健康公司的一个部门，最近担任高级副总裁兼美国视力保健业务总经理。在加入Bausch + Lomb（NYSE：BLCO）之前，他曾在JNJ（NYSE：TERM3）担任多个职位。McKenna先生获得了亚利桑那州立大学市场营销学士学位和Azusa太平洋大学工商管理硕士学位。我们认为，McKenna先生作为生物制药行业执行官的丰富经验使他完全有资格担任Perceptive Capital Solutions Corp董事会成员。
Mark C. McKenna has served as a member of Perceptive Capital Solutions Corp board of directors since June 2024. Mr. McKenna has served as a director at New Amsterdam Pharma (Nasdaq: NAMS), a clinical biopharmaceutical company, since July 2024, as founder, Chief Executive Officer and Chairman of Mirador Therapeutics, Inc., a biotechnology company, since March 2024, as a director of Spyre Therapeutics, Inc. (Nasdaq: SYRE) since February 2024, as Venture Partner at Arch Venture Partner since February 2024, as Senior Advisor at Fairmount Funds Management LLC, a healthcare investment firm, since October 2023 and as chair of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: AGE) since Augt 2023. Mr. McKenna has also served as Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases, since June 2023. Mr. McKenna most recently served as a director of Helix Acquisition Corp. II (Nasdaq: HLXB) ("Helix") from February 2024 to Augt 2025. Prior to Helix, he served as President and Chief Executive Officer and as a member of the board of directors of Promethe, a clinical stage biotechnology company, from September 2019 to June 2023, when Promethe was acquired by Merck & Co., Inc. (NYSE: MRK), and as Chairman of the board of Promethe from Augt 2021 to June 2023. Prior to Promethe, he served as President of Salix Pharmaceuticals, Inc. ("Salix"), a pharmaceutical company and wholly owned subsidiary of Bach Health Companies, Inc. (NYSE: BHC), from March 2016 through Augt 2019. Prior to Salix, Mr. McKenna spent more than a decade in vario roles with Bach + Lomb, also a division of Bach Health Companies, Inc., most recently as Senior Vice President and General Manager of its U.S. Vision Care biness. Before joining Bach + Lomb (NYSE: BLCO), he held several positions with Johnson & Johnson (NYSE: JNJ). Mr. McKenna received a B.S. in Marketing from Arizona State University and an M.B.A. from Aza Pacific University. - Mark C. McKenna，已同意在Perceptive Capital Solutions Corp董事会任职。McKenna先生自2024年2月起担任Spyre Therapeutics，Inc.（纳斯达克：SYRE）的董事，自2024年2月起担任Helix Acquisition Corp. II（纳斯达克：HLXB）的董事，自2024年2月起担任Arch Venture Partner的风险合伙人，自2023年8月起担任Apogee Therapeutics，Inc.（纳斯达克：AGE）的董事会主席。自2023年6月以来，McKenna先生还担任McKenna Capital Partners的首席投资官和董事总经理，这是一家致力于投资于使人衰弱的疾病的突破性治疗的家族办公室。McKenna先生最近于2019年9月至2023年6月（当时Prometheus被默克制药公司（NYSE：MRK）收购）期间担任临床阶段生物技术公司Prometheus Biosciences, Inc.（“Prometheus”）的总裁兼首席执行官和董事会成员，并于2021年8月至2023年6月担任Prometheus董事会主席。在加入普罗米修斯之前，他曾于2016年3月至2019年8月担任柳药医疗，Inc.（“Salix”）总裁，该公司是一家制药公司，是Bausch Health健康公司（纽约证券交易所代码：BHC）的全资子公司。在加入Salix之前，McKenna先生曾在Bausch + Lomb担任过十多年的各种职务，该公司也是Bausch Health健康公司的一个部门，最近担任高级副总裁兼美国视力保健业务总经理。在加入Bausch + Lomb（NYSE：BLCO）之前，他曾在JNJ（NYSE：TERM3）担任多个职位。McKenna先生获得了亚利桑那州立大学市场营销学士学位和Azusa太平洋大学工商管理硕士学位。我们认为，McKenna先生作为生物制药行业执行官的丰富经验使他完全有资格担任Perceptive Capital Solutions Corp董事会成员。
- Mark C. McKenna has served as a member of Perceptive Capital Solutions Corp board of directors since June 2024. Mr. McKenna has served as a director at New Amsterdam Pharma (Nasdaq: NAMS), a clinical biopharmaceutical company, since July 2024, as founder, Chief Executive Officer and Chairman of Mirador Therapeutics, Inc., a biotechnology company, since March 2024, as a director of Spyre Therapeutics, Inc. (Nasdaq: SYRE) since February 2024, as Venture Partner at Arch Venture Partner since February 2024, as Senior Advisor at Fairmount Funds Management LLC, a healthcare investment firm, since October 2023 and as chair of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: AGE) since Augt 2023. Mr. McKenna has also served as Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office dedicated to investing in breakthrough treatments for debilitating diseases, since June 2023. Mr. McKenna most recently served as a director of Helix Acquisition Corp. II (Nasdaq: HLXB) ("Helix") from February 2024 to Augt 2025. Prior to Helix, he served as President and Chief Executive Officer and as a member of the board of directors of Promethe, a clinical stage biotechnology company, from September 2019 to June 2023, when Promethe was acquired by Merck & Co., Inc. (NYSE: MRK), and as Chairman of the board of Promethe from Augt 2021 to June 2023. Prior to Promethe, he served as President of Salix Pharmaceuticals, Inc. ("Salix"), a pharmaceutical company and wholly owned subsidiary of Bach Health Companies, Inc. (NYSE: BHC), from March 2016 through Augt 2019. Prior to Salix, Mr. McKenna spent more than a decade in vario roles with Bach + Lomb, also a division of Bach Health Companies, Inc., most recently as Senior Vice President and General Manager of its U.S. Vision Care biness. Before joining Bach + Lomb (NYSE: BLCO), he held several positions with Johnson & Johnson (NYSE: JNJ). Mr. McKenna received a B.S. in Marketing from Arizona State University and an M.B.A. from Aza Pacific University.
- John Kastelein
-
John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
John Kastelein has served as Chief Scientific Officer and non executive director since November 2022. Dr. Kastelein co founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emerit professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP inhibition in the New England Jnal of Medicine in 1997. - John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
- John Kastelein has served as Chief Scientific Officer and non executive director since November 2022. Dr. Kastelein co founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emerit professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP inhibition in the New England Jnal of Medicine in 1997.
- Janneke van der Kamp
-
Janneke van der Kamp目前担任Gr ü nenthal的首席商务官，此前在诺华担任了20年的职责，最终在制药执行委员会担任产品和投资组合战略全球主管，然后在2017年1月至2022年1月期间担任欧洲制药区域主管。在诺华期间，van der Kamp女士支持推出诺华的关键心血管疾病药物，以及该公司在免疫学、皮肤病学、神经科学、眼科和呼吸系统疾病方面的努力。van der Kamp女士获得了乌得勒支大学的化学硕士学位和欧洲工商管理学院的工商管理硕士学位。
Janneke van der Kamp has served as a member of the Board of Directors since April 2023. Ms. van der Kamp currently serves as the Chief Executive Officer of Norgine. Prior to this, she was Chief Commercial Officer of Grünenthal and previoly spent two decades in roles of increasing responsibility at Novartis, ultimately serving on the Pharma Executive Committee as Global Head of Product & Portfolio Strategy from 2016 to 2018 and then Head of Pharma Region Europe from 2019 until 2022. While at Novartis, Ms. van der Kamp supported the launch of Novartis' key cardiovascular disease medicines, as ll as the company's efforts in immunology, dermatology, neuroscience, ophthalmology, and respiratory disease. Ms. van der Kamp received her M.S. in chemistry from Utrecht University and M.B.A. from INSEAD. - Janneke van der Kamp目前担任Gr ü nenthal的首席商务官，此前在诺华担任了20年的职责，最终在制药执行委员会担任产品和投资组合战略全球主管，然后在2017年1月至2022年1月期间担任欧洲制药区域主管。在诺华期间，van der Kamp女士支持推出诺华的关键心血管疾病药物，以及该公司在免疫学、皮肤病学、神经科学、眼科和呼吸系统疾病方面的努力。van der Kamp女士获得了乌得勒支大学的化学硕士学位和欧洲工商管理学院的工商管理硕士学位。
- Janneke van der Kamp has served as a member of the Board of Directors since April 2023. Ms. van der Kamp currently serves as the Chief Executive Officer of Norgine. Prior to this, she was Chief Commercial Officer of Grünenthal and previoly spent two decades in roles of increasing responsibility at Novartis, ultimately serving on the Pharma Executive Committee as Global Head of Product & Portfolio Strategy from 2016 to 2018 and then Head of Pharma Region Europe from 2019 until 2022. While at Novartis, Ms. van der Kamp supported the launch of Novartis' key cardiovascular disease medicines, as ll as the company's efforts in immunology, dermatology, neuroscience, ophthalmology, and respiratory disease. Ms. van der Kamp received her M.S. in chemistry from Utrecht University and M.B.A. from INSEAD.
- Wouter Joustra
-
Wouter Jotra自2024年7月起担任董事会成员。Wouter Jotra是欧洲领先的生命科学风险投资公司Forbion的普通合伙人。在Forbion，Jotra先生负责普通基金管理、私人、交叉和公共投资。Jotra先生专注于Forbion的增长机会基金，该基金专注于投资晚期生命科学公司。在2019年加入Forbion之前，Jotra Previoly先生是一名高级交易员，担任欧洲精品投资银行Kempen生命科学专营权的执行董事会成员。Jotra先生还担任Gyroscope Therapeutics的董事会成员，直到该公司于2022年2月被诺华公司以高达15亿美元的价格收购完成，VectivBio（NASDAQ：VECT）的董事会从2022年12月到2023年12月被Ironwood医药公司以12亿美元收购完成，Aiolos Bio的董事会直到2024年2月GSK plc以高达14亿美元的价格完成收购，以及Forbion的SPAC工具的董事会，直到2023年10月完成与enGene Holdings Inc.（NASDAQ：ENGN）的biness合并。Jotra先生目前在VectorY Therapeutics、NewAmsterdam Pharma N.V.（NASDAQ：NAMS）、Beacon Therapeutics、Navigator Medicines、Verdiva Bio和VOR Biopharma（NASDAQ：VOR）的董事会任职。Jotra先生拥有格罗宁根大学BINCE Administration理学硕士学位，以及同一所大学的国际BINCE和管理理学学士学位。
Wouter Joustra has served as a member of the Board of Directors since July 2024. Wouter Jotra is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, Mr. Jotra is responsible for general fund management, private, cross over and public investments. Mr. Jotra foces on Forbion's Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Prior to joining Forbion in 2019, Mr. Jotra previoly was a Senior Trader, as ll as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. Mr. Jotra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion's SPAC vehicle until the completion of the biness combination of enGene Holdings Inc. (NASDAQ: ENGN) in October 2023. Currently Mr. Jotra serves on the board of directors of VectorY Therapeutics, NewAmsterdam Pharma N.V. (NASDAQ: NAMS), Beacon Therapeutics, Navigator Medicines, Verdiva Bio and VOR Biopharma (NASDAQ: VOR). Mr. Jotra holds an M.Sc. in Biness Administration from the University of Groningen, and a B.Sc. in International Biness and Management from this same university. - Wouter Jotra自2024年7月起担任董事会成员。Wouter Jotra是欧洲领先的生命科学风险投资公司Forbion的普通合伙人。在Forbion，Jotra先生负责普通基金管理、私人、交叉和公共投资。Jotra先生专注于Forbion的增长机会基金，该基金专注于投资晚期生命科学公司。在2019年加入Forbion之前，Jotra Previoly先生是一名高级交易员，担任欧洲精品投资银行Kempen生命科学专营权的执行董事会成员。Jotra先生还担任Gyroscope Therapeutics的董事会成员，直到该公司于2022年2月被诺华公司以高达15亿美元的价格收购完成，VectivBio（NASDAQ：VECT）的董事会从2022年12月到2023年12月被Ironwood医药公司以12亿美元收购完成，Aiolos Bio的董事会直到2024年2月GSK plc以高达14亿美元的价格完成收购，以及Forbion的SPAC工具的董事会，直到2023年10月完成与enGene Holdings Inc.（NASDAQ：ENGN）的biness合并。Jotra先生目前在VectorY Therapeutics、NewAmsterdam Pharma N.V.（NASDAQ：NAMS）、Beacon Therapeutics、Navigator Medicines、Verdiva Bio和VOR Biopharma（NASDAQ：VOR）的董事会任职。Jotra先生拥有格罗宁根大学BINCE Administration理学硕士学位，以及同一所大学的国际BINCE和管理理学学士学位。
- Wouter Joustra has served as a member of the Board of Directors since July 2024. Wouter Jotra is a General Partner at Forbion, a leading European life sciences venture capital firm. At Forbion, Mr. Jotra is responsible for general fund management, private, cross over and public investments. Mr. Jotra foces on Forbion's Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Prior to joining Forbion in 2019, Mr. Jotra previoly was a Senior Trader, as ll as Executive Board member of the Life Sciences franchise at Kempen, a European boutique investment bank. Mr. Jotra also served as a member of the board of directors of Gyroscope Therapeutics until the closing of its acquisition by Novartis in February 2022 for up to $1.5 billion, the board of directors of VectivBio (NASDAQ: VECT) from December 2022 until the closing of its $1.2 billion acquisition by Ironwood Pharmaceuticals in December 2023, the board of directors of Aiolos Bio until the closing of its acquisition by GSK plc in February 2024 for up to $1.4 billion and the board of Forbion's SPAC vehicle until the completion of the biness combination of enGene Holdings Inc. (NASDAQ: ENGN) in October 2023. Currently Mr. Jotra serves on the board of directors of VectorY Therapeutics, NewAmsterdam Pharma N.V. (NASDAQ: NAMS), Beacon Therapeutics, Navigator Medicines, Verdiva Bio and VOR Biopharma (NASDAQ: VOR). Mr. Jotra holds an M.Sc. in Biness Administration from the University of Groningen, and a B.Sc. in International Biness and Management from this same university.
- James N. Topper
-
James N. Topper，医学博士，担任首席执行官兼董事会主席。Topper博士目前是Frazier Life Sciences的管理合伙人。他于2003年加入弗雷泽，并于同年开设了弗雷泽的门洛帕克办事处。在15年的管理合伙人生涯中，Topper博士投资了超过35家公司，涵盖了广泛的生命科学和生物制药公司。Topper博士领导并担任过弗雷泽许多成功的生命科学投资的董事会成员，包括出售给阿斯利康的Acerta Pharma BV、Calistoga Pharmaceuticals（联合创始人，出售给Gilead Sciences）、Mavupharma（出售给艾伯维）、Rempex（出售给The Medicines Company）、Incline（联合创始人，出售给The Medicines Company）、Alnara（出售给礼来）、Portola（联合创始人，纳斯达克股票代码：PTLA）、CoTherix（出售给Actelion）和Threshold（纳斯达克股票代码：THLD）。他目前在Allena制药（纳斯达克股票代码：ALNA）、Alpine Immune科学（纳斯达克股票代码：ALPN）、Amunix制药、AnaptysBio（纳斯达克股票代码：ANAB）、Lassen Therapeutics、Seraxis Holdings，Inc.和Phathom制药（纳斯达克股票代码：PHAT）中代表弗雷泽参选。2011年和2016年，托珀博士入选Midas最佳风险投资家榜单，2013年，托珀博士被《福布斯》评为十大医疗保健投资者。
James N. Topper has served as a member of the Board of Directors since November 2022. Dr. Topper previoly served as FLAC's Chief Executive Officer and Chairman of the FLAC Board of Directors from October 2020 until November 2022. Dr. Topper currently serves as a Managing Partner of Frazier Life Sciences ("Frazier"). He joined Frazier in 2003 and opened Frazier's Menlo Park office in the same year. Throughout his tenure as a Managing Partner, Dr. Topper has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Alpine Immune Sciences (sold to Vertex), Amunix Pharmaceuticals, Inc. (sold to Sanofi), Aptinyx Inc. (Nasdaq: APTX), Calistoga Pharmaceuticals, Inc. (co founder, sold to Gilead Sciences), Entasis Therapeutics Holdings Inc. (sold to Innoviva), Frazier Lifesciences Acquisition Corporation, Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola, Inc. (co founder, Nasdaq: PTLA), Phathom Pharmaceuticals Inc. (Nasdaq: PHAT), CoTherix, Inc (sold to Actelion), and Threshold Pharmaceutical, Inc. (Nasdaq: THLD). He currently represents Frazier on the boards of companies such as Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), Diagonal Therapeutics, Inc., Counterakt Therapeutics, Inc., Enlaza Therapeutics, Inc., Attovia Therapeutics, Inc., and Architect Therapeutics, Inc. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013, Dr. Topper was recognized by Forbes as a top ten healthcare investor. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford and his B.S. from the University of Michigan. - James N. Topper，医学博士，担任首席执行官兼董事会主席。Topper博士目前是Frazier Life Sciences的管理合伙人。他于2003年加入弗雷泽，并于同年开设了弗雷泽的门洛帕克办事处。在15年的管理合伙人生涯中，Topper博士投资了超过35家公司，涵盖了广泛的生命科学和生物制药公司。Topper博士领导并担任过弗雷泽许多成功的生命科学投资的董事会成员，包括出售给阿斯利康的Acerta Pharma BV、Calistoga Pharmaceuticals（联合创始人，出售给Gilead Sciences）、Mavupharma（出售给艾伯维）、Rempex（出售给The Medicines Company）、Incline（联合创始人，出售给The Medicines Company）、Alnara（出售给礼来）、Portola（联合创始人，纳斯达克股票代码：PTLA）、CoTherix（出售给Actelion）和Threshold（纳斯达克股票代码：THLD）。他目前在Allena制药（纳斯达克股票代码：ALNA）、Alpine Immune科学（纳斯达克股票代码：ALPN）、Amunix制药、AnaptysBio（纳斯达克股票代码：ANAB）、Lassen Therapeutics、Seraxis Holdings，Inc.和Phathom制药（纳斯达克股票代码：PHAT）中代表弗雷泽参选。2011年和2016年，托珀博士入选Midas最佳风险投资家榜单，2013年，托珀博士被《福布斯》评为十大医疗保健投资者。
- James N. Topper has served as a member of the Board of Directors since November 2022. Dr. Topper previoly served as FLAC's Chief Executive Officer and Chairman of the FLAC Board of Directors from October 2020 until November 2022. Dr. Topper currently serves as a Managing Partner of Frazier Life Sciences ("Frazier"). He joined Frazier in 2003 and opened Frazier's Menlo Park office in the same year. Throughout his tenure as a Managing Partner, Dr. Topper has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Alpine Immune Sciences (sold to Vertex), Amunix Pharmaceuticals, Inc. (sold to Sanofi), Aptinyx Inc. (Nasdaq: APTX), Calistoga Pharmaceuticals, Inc. (co founder, sold to Gilead Sciences), Entasis Therapeutics Holdings Inc. (sold to Innoviva), Frazier Lifesciences Acquisition Corporation, Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola, Inc. (co founder, Nasdaq: PTLA), Phathom Pharmaceuticals Inc. (Nasdaq: PHAT), CoTherix, Inc (sold to Actelion), and Threshold Pharmaceutical, Inc. (Nasdaq: THLD). He currently represents Frazier on the boards of companies such as Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), Diagonal Therapeutics, Inc., Counterakt Therapeutics, Inc., Enlaza Therapeutics, Inc., Attovia Therapeutics, Inc., and Architect Therapeutics, Inc. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013, Dr. Topper was recognized by Forbes as a top ten healthcare investor. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford and his B.S. from the University of Michigan.
- William H. Lewis
-
William H. Lewis是Aegerion的联合创始人，他从2009年8月开始一直担任总裁。在这之前，从2005年3月到2009年8月，他担任我司首席财务官，从2005年7月到2007年8月，担任我司秘书、财务总监兼行政部副总裁，从2007年2月到2009年2月，担任我司财务与行政部高级副总裁，从2009年2月到2009年8月，担任我司财务与行政部执行副总裁。从2004年8月到2005年3月，Lewis先生担任一家对冲基金的常务董事，他在那里致力于投资小市值公司。在这之前，他担任富国证券（Wells Fargo Securities）的常务董事，担任资本市场投资银行业务（Capital Markets Investment Banking）的负责人，他在该公司负责发起、监管并实施私人与公共债务与股权交易。在这之前，Lewis先生担任罗伯逊史蒂芬斯公司（Robertson Stephens & Company）的负责人，他在该公司负责监管私人与公共债务与股权交易，并担任摩根大通（J.P. Morgan）的副总裁，他在该公司专注于在美国和欧洲进行私人与公众股权发行。Lewis先生在欧柏林大学（Oberlin College）以优异成绩获得文学学士学位，并在美国凯斯西储大学（Case Western Reserve University）以优异成绩获得工商管理硕士学位与法学博士学位。
William H. Lewis,Career Highlights:Aegerion Pharmaceuticals, Inc. Nasdaq: AEGR (Aegerion) (2005 - 2011),Co-founder,President,Chief Financial Officer,Wells Fargo & Co. (2002 - 2004),Robertson Stephens Capital (2000 - 2002),JP Morgan Chase & Co. (1995 - 2000),Foreign Service for the U.S. Government (1989 - 1992),Oberlin College - B.A.,Case Western Reserve University - M.B.A.,Case Western Reserve University - J.D.. - William H. Lewis是Aegerion的联合创始人，他从2009年8月开始一直担任总裁。在这之前，从2005年3月到2009年8月，他担任我司首席财务官，从2005年7月到2007年8月，担任我司秘书、财务总监兼行政部副总裁，从2007年2月到2009年2月，担任我司财务与行政部高级副总裁，从2009年2月到2009年8月，担任我司财务与行政部执行副总裁。从2004年8月到2005年3月，Lewis先生担任一家对冲基金的常务董事，他在那里致力于投资小市值公司。在这之前，他担任富国证券（Wells Fargo Securities）的常务董事，担任资本市场投资银行业务（Capital Markets Investment Banking）的负责人，他在该公司负责发起、监管并实施私人与公共债务与股权交易。在这之前，Lewis先生担任罗伯逊史蒂芬斯公司（Robertson Stephens & Company）的负责人，他在该公司负责监管私人与公共债务与股权交易，并担任摩根大通（J.P. Morgan）的副总裁，他在该公司专注于在美国和欧洲进行私人与公众股权发行。Lewis先生在欧柏林大学（Oberlin College）以优异成绩获得文学学士学位，并在美国凯斯西储大学（Case Western Reserve University）以优异成绩获得工商管理硕士学位与法学博士学位。
- William H. Lewis,Career Highlights:Aegerion Pharmaceuticals, Inc. Nasdaq: AEGR (Aegerion) (2005 - 2011),Co-founder,President,Chief Financial Officer,Wells Fargo & Co. (2002 - 2004),Robertson Stephens Capital (2000 - 2002),JP Morgan Chase & Co. (1995 - 2000),Foreign Service for the U.S. Government (1989 - 1992),Oberlin College - B.A.,Case Western Reserve University - M.B.A.,Case Western Reserve University - J.D..
- John W. Smither
-
John W. Smither自2019年5月起担任Arcutis Biotherapeutics, Inc.首席财务官。Smither先生此前曾于2016年1月至2017年3月担任Sienna Biopharmaceuticals，Inc.的首席财务官，并于2018年4月至2019年4月再次担任该职务。2017年10月至2018年3月，他在Kite Pharma与吉利德科学公司整合期间担任临时首席财务官，在此之前，于2016年1月至2017年7月在Unity Biotechnology，Inc.担任首席财务官。更早之前，他曾于2007年11月在Kythera生物制药，Inc.担任首席财务官，直到该公司于2015年10月被Allergan plc收购。1998年至2007年，Smither先生曾在安进公司担任多个职务，包括公司会计主管、安进欧洲分部财务和行政副总裁以及内部审计主管。在加入安进之前，他曾在公共会计师事务所Ernst & Young LLP担任审计合伙人，随后在Ernst & Young担任多家早期公司的首席财务官。Smither先生目前在Achaogen, Inc.的董事会任职。此前，Smither先生曾在Principia Biopharma Inc.生物制药公司的董事会任职。他曾获得洛杉矶加利福尼亚州立大学工商管理学士学位。Smither先生是一名非在职注册会计师，是美国注册会计师协会、加州注册会计师协会和国际财务主管协会的成员。
John W. Smither has served as a member of the Board of Directors since January 2023. Mr. Smither previoly served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) from May 2019 until March 2021, and again as Interim Chief Financial Officer from September 2023 to April 2024, and the Chief Financial Officer of Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA) from April 2018 until March 2019. Mr. Smither also served as the interim Chief Financial Officer at Kite Pharma (a Gilead Sciences, Inc. company) from October 2017 until April 2018 during its integration with Gilead. Mr. Smither presently serves on the board of directors of Genelux serving as chair of its compensation committee and as a member of its audit committee. Mr. Smither also served on the board of directors and audit committee chair of eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) from March 2018 to September 2023 and Applied Molecular Transport, Inc. (Nasdaq: AMTI) from January 2022 to December 2023. Mr. Smither also served as a member of the nomination and corporate governance committee of eFFECTOR Therapeutics and the compensation committee of Applied Molecular Transport. Mr. Smither previoly served on the board of directors of Achaogen, Inc. and Principia Biopharma Inc and as the chair of their audit committees. Mr. Smither also has 15 years' experience as a practicing CPA (inactive), including time spent as an audit partner with Ernst & Young LLP. - John W. Smither自2019年5月起担任Arcutis Biotherapeutics, Inc.首席财务官。Smither先生此前曾于2016年1月至2017年3月担任Sienna Biopharmaceuticals，Inc.的首席财务官，并于2018年4月至2019年4月再次担任该职务。2017年10月至2018年3月，他在Kite Pharma与吉利德科学公司整合期间担任临时首席财务官，在此之前，于2016年1月至2017年7月在Unity Biotechnology，Inc.担任首席财务官。更早之前，他曾于2007年11月在Kythera生物制药，Inc.担任首席财务官，直到该公司于2015年10月被Allergan plc收购。1998年至2007年，Smither先生曾在安进公司担任多个职务，包括公司会计主管、安进欧洲分部财务和行政副总裁以及内部审计主管。在加入安进之前，他曾在公共会计师事务所Ernst & Young LLP担任审计合伙人，随后在Ernst & Young担任多家早期公司的首席财务官。Smither先生目前在Achaogen, Inc.的董事会任职。此前，Smither先生曾在Principia Biopharma Inc.生物制药公司的董事会任职。他曾获得洛杉矶加利福尼亚州立大学工商管理学士学位。Smither先生是一名非在职注册会计师，是美国注册会计师协会、加州注册会计师协会和国际财务主管协会的成员。
- John W. Smither has served as a member of the Board of Directors since January 2023. Mr. Smither previoly served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) from May 2019 until March 2021, and again as Interim Chief Financial Officer from September 2023 to April 2024, and the Chief Financial Officer of Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA) from April 2018 until March 2019. Mr. Smither also served as the interim Chief Financial Officer at Kite Pharma (a Gilead Sciences, Inc. company) from October 2017 until April 2018 during its integration with Gilead. Mr. Smither presently serves on the board of directors of Genelux serving as chair of its compensation committee and as a member of its audit committee. Mr. Smither also served on the board of directors and audit committee chair of eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) from March 2018 to September 2023 and Applied Molecular Transport, Inc. (Nasdaq: AMTI) from January 2022 to December 2023. Mr. Smither also served as a member of the nomination and corporate governance committee of eFFECTOR Therapeutics and the compensation committee of Applied Molecular Transport. Mr. Smither previoly served on the board of directors of Achaogen, Inc. and Principia Biopharma Inc and as the chair of their audit committees. Mr. Smither also has 15 years' experience as a practicing CPA (inactive), including time spent as an audit partner with Ernst & Young LLP.
高管简历
中英对照 | 中文 | 英文- Michael Davidson
Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
Michael Davidson has served as Chief Executive Officer and executive director since November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from Augt 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid loring drugs, and omega 3 fatty acids. Dr. Davidson is board certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX), and BioAge Labs, Inc. (Nasdaq: BIOA). Dr. Davidson also serves on the boards of f private biotechnology companies, Sonothera, Jocasta Neuroscience and Abcentra. Dr. Davidson received his B.A. and M.S. from Northstern University and his M.D. from The Ohio State University School of Medicine.- Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
- Michael Davidson has served as Chief Executive Officer and executive director since November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from Augt 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid loring drugs, and omega 3 fatty acids. Dr. Davidson is board certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX), and BioAge Labs, Inc. (Nasdaq: BIOA). Dr. Davidson also serves on the boards of f private biotechnology companies, Sonothera, Jocasta Neuroscience and Abcentra. Dr. Davidson received his B.A. and M.S. from Northstern University and his M.D. from The Ohio State University School of Medicine.
- John Kastelein
John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
John Kastelein has served as Chief Scientific Officer and non executive director since November 2022. Dr. Kastelein co founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emerit professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP inhibition in the New England Jnal of Medicine in 1997.- John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
- John Kastelein has served as Chief Scientific Officer and non executive director since November 2022. Dr. Kastelein co founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emerit professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP inhibition in the New England Jnal of Medicine in 1997.
- Louise Kooij
Louise Kooij，于2023年3月被任命为公司临时首席财务官。Kooij女士于2020年5月加入公司担任公司首席财务官。2023年1月，Kooij女士被任命为公司首席会计官，并在该职位上任职至2023年3月。Kooij女士此前在跨国生物技术公司Genzyme Europe B.V.担任过14年的各种财务职务。自2020年5月以来，Kooij女士还担任独立顾问，担任其他私营生物技术初创企业的首席财务官。2016年1月至2018年4月，Kooij女士领导Genzyme在欧洲的业务运营团队，并从2018年4月至2020年5月，担任Genzyme在中欧和东欧的罕见病部门负责人。Kooij女士获得了Nyenrode商业大学的硕士学位和Hogeschool Markus Verbeek的审计学位。
Louise Kooij joined the Company as its Chief Financial Officer in May 2020. In January 2023, Ms. Kooij was appointed as the Company's Chief Accounting Officer and served in that role until March 2023 when she was appointed Interim Chief Financial Officer. In October 2023 Ms. Kooij was appointed as the Company's Chief Accounting Officer. Ms. Kooij previoly spent 18 years working in vario finance roles at Genzyme Europe B.V. ("Genzyme"), a multinational biotechnology company. During her tenure at Genzyme, she led the European and Global FP&A team, many European finance projects, the European integration of Genzyme into Sanofi, the integration of acquisitions into Sanofi, the European Biness Operations Team as ll as the Rare Disease unit in Central and Eastern Europe. Before joining Genzyme, Ms. Kooij worked as a certified auditor at PricewaterhoeCoopers as ll as other audit firms for seven years. Since May 2020, Ms. Kooij has also served as an independent consultant in the role of chief financial officer to other private biotechnology start ups. Ms. Kooij received a master's degree from Nyenrode Biness University and her auditing degree from Hogeschool Mark Verbeek.- Louise Kooij，于2023年3月被任命为公司临时首席财务官。Kooij女士于2020年5月加入公司担任公司首席财务官。2023年1月，Kooij女士被任命为公司首席会计官，并在该职位上任职至2023年3月。Kooij女士此前在跨国生物技术公司Genzyme Europe B.V.担任过14年的各种财务职务。自2020年5月以来，Kooij女士还担任独立顾问，担任其他私营生物技术初创企业的首席财务官。2016年1月至2018年4月，Kooij女士领导Genzyme在欧洲的业务运营团队，并从2018年4月至2020年5月，担任Genzyme在中欧和东欧的罕见病部门负责人。Kooij女士获得了Nyenrode商业大学的硕士学位和Hogeschool Markus Verbeek的审计学位。
- Louise Kooij joined the Company as its Chief Financial Officer in May 2020. In January 2023, Ms. Kooij was appointed as the Company's Chief Accounting Officer and served in that role until March 2023 when she was appointed Interim Chief Financial Officer. In October 2023 Ms. Kooij was appointed as the Company's Chief Accounting Officer. Ms. Kooij previoly spent 18 years working in vario finance roles at Genzyme Europe B.V. ("Genzyme"), a multinational biotechnology company. During her tenure at Genzyme, she led the European and Global FP&A team, many European finance projects, the European integration of Genzyme into Sanofi, the integration of acquisitions into Sanofi, the European Biness Operations Team as ll as the Rare Disease unit in Central and Eastern Europe. Before joining Genzyme, Ms. Kooij worked as a certified auditor at PricewaterhoeCoopers as ll as other audit firms for seven years. Since May 2020, Ms. Kooij has also served as an independent consultant in the role of chief financial officer to other private biotechnology start ups. Ms. Kooij received a master's degree from Nyenrode Biness University and her auditing degree from Hogeschool Mark Verbeek.
- Ian Somaiya
Ian Somaiya于2023年10月加入公司，担任首席财务官。Somaiya先生在金融和生物技术领域拥有超过25年的经验。最近，Somaiya先生于2021年11月至2023年7月期间担任Elucida Oncology，Inc.的首席财务和Biness官，负责筹资和整体公司战略。从2018年4月到2021年11月，Somaiya先生担任TCR2 Therapeutics，Inc.（“TCR2”）的首席财务官，在那里他成功地通过了公司的首次公开募股和两次后续股权融资，总共筹集了超过3.5亿美元。在TCR2任职期间，Somaiya先生领导了公司的财务和上市公司报告职能，以及BINCE Development和投资者关系职能。在加入TCR2之前，Somaiya先生在华尔街工作了20多年，在那里他对100多家生物技术公司进行了广泛的研究，涉及不同的治疗领域、技术平台和发展阶段。Somaiya先生曾在BMO资本市场担任董事总经理兼生物技术研究主管，并曾在Nomura Securities Co. Ltd.、Piper Jaffray Companies和Thomas isel Partners Group，Inc.担任董事总经理和股票分析师。Somaiya先生的职业生涯始于摩根士丹利和保德信证券的研究分析师，并因其在2006、2007和2008年对生物技术的报道而被华尔街日报评为“华尔街最佳”。Somaiya先生获得了纽约大学生物学和神经科学的文学学士学位。
Ian Somaiya joined the Company in October 2023 as its Chief Financial Officer. Mr. Somaiya has over 25 years of experience in finance and biotechnology. Most recently, Mr. Somaiya served as the Chief Financial and Biness Officer at Elucida Oncology, Inc. from November 2021 until July 2023, where he was responsible for fundraising and overall corporate strategy. From April 2018 until November 2021, Mr. Somaiya served as the Chief Financial Officer of TCR2 Therapeutics, Inc. ("TCR2") where he successfully navigated the company through its initial public offering and two follow on equity financings, raising more than $350 million in the aggregate. During his tenure at TCR2, Mr. Somaiya led the company's finance and public company reporting functions, as ll as the biness development and investor relations functions. Prior to joining TCR2, Mr. Somaiya spent over 20 years on Wall Street where he conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. Mr. Somaiya served as a Managing Director and Head of Biotechnology Research at BMO Capital Markets and served as a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Piper Jaffray Companies and Thomas isel Partners Group, Inc. Mr. Somaiya began his career as a research analyst at Morgan Stanley and Prudential Securities and was recognized as "Best on the Street" by the Wall Street Jnal for his coverage on biotechnology in 2006, 2007 and 2008. Mr. Somaiya received a Bachelor of Arts degree in biology and neuroscience from New York University.- Ian Somaiya于2023年10月加入公司，担任首席财务官。Somaiya先生在金融和生物技术领域拥有超过25年的经验。最近，Somaiya先生于2021年11月至2023年7月期间担任Elucida Oncology，Inc.的首席财务和Biness官，负责筹资和整体公司战略。从2018年4月到2021年11月，Somaiya先生担任TCR2 Therapeutics，Inc.（“TCR2”）的首席财务官，在那里他成功地通过了公司的首次公开募股和两次后续股权融资，总共筹集了超过3.5亿美元。在TCR2任职期间，Somaiya先生领导了公司的财务和上市公司报告职能，以及BINCE Development和投资者关系职能。在加入TCR2之前，Somaiya先生在华尔街工作了20多年，在那里他对100多家生物技术公司进行了广泛的研究，涉及不同的治疗领域、技术平台和发展阶段。Somaiya先生曾在BMO资本市场担任董事总经理兼生物技术研究主管，并曾在Nomura Securities Co. Ltd.、Piper Jaffray Companies和Thomas isel Partners Group，Inc.担任董事总经理和股票分析师。Somaiya先生的职业生涯始于摩根士丹利和保德信证券的研究分析师，并因其在2006、2007和2008年对生物技术的报道而被华尔街日报评为“华尔街最佳”。Somaiya先生获得了纽约大学生物学和神经科学的文学学士学位。
- Ian Somaiya joined the Company in October 2023 as its Chief Financial Officer. Mr. Somaiya has over 25 years of experience in finance and biotechnology. Most recently, Mr. Somaiya served as the Chief Financial and Biness Officer at Elucida Oncology, Inc. from November 2021 until July 2023, where he was responsible for fundraising and overall corporate strategy. From April 2018 until November 2021, Mr. Somaiya served as the Chief Financial Officer of TCR2 Therapeutics, Inc. ("TCR2") where he successfully navigated the company through its initial public offering and two follow on equity financings, raising more than $350 million in the aggregate. During his tenure at TCR2, Mr. Somaiya led the company's finance and public company reporting functions, as ll as the biness development and investor relations functions. Prior to joining TCR2, Mr. Somaiya spent over 20 years on Wall Street where he conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. Mr. Somaiya served as a Managing Director and Head of Biotechnology Research at BMO Capital Markets and served as a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Piper Jaffray Companies and Thomas isel Partners Group, Inc. Mr. Somaiya began his career as a research analyst at Morgan Stanley and Prudential Securities and was recognized as "Best on the Street" by the Wall Street Jnal for his coverage on biotechnology in 2006, 2007 and 2008. Mr. Somaiya received a Bachelor of Arts degree in biology and neuroscience from New York University.